Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ purged stem cells
- Development stage
- Unknown
- Lead developer
- The Catholic University of Korea
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ purged stem cells refer to an autologous hematopoietic stem cell graft that has undergone ex vivo processing to enrich for CD34+ progenitor cells while depleting contaminating malignant cells. This process, often performed using immunomagnetic separation devices like the CliniMACS system, is utilized in autologous stem cell transplantation (ASCT) for hematologic malignancies such as peripheral T-cell lymphoma (PTCL). Since most PTCL cells do not express the CD34 antigen, positive selection of CD34+ cells effectively "purges" the graft of tumor cells, potentially reducing the risk of relapse post-transplant. Clinical data suggests that using purged grafts can improve overall survival and disease-free survival in high-risk PTCL patients compared to unpurged grafts, without significantly delaying hematopoietic engraftment.
- Other names
- CD34+ purged stem cellsCD34+ selected autologous stem cellsCD34+ enriched hematopoietic progenitor cellspurged autologous stem cell graft
Beyond the preview
Go deeper on CD34+ purged stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ purged stem cells.